Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.
about
Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters CommitteeOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisRectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approachAdvances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative dataOral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine.European evidence-based Consensus on the management of ulcerative colitis: Current management.Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study.DNA flow cytometric evaluation of cell cycle distribution in ulcerative colitis: a proposed method for assessing severity of disease.Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.Medical management of inflammatory bowel disease in the new millennium.High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitisA new look at a mainstay ulcerative colitis therapyOutpatient management of inflammatory bowel disease. Let's keep it as simple as possible.Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.How effective are the usual treatments for ulcerative colitis?Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.p53 mutation in patients with ulcerative colitis in rectal biopsySystematic review: the use of mesalazine in inflammatory bowel disease.The role of mesalamine in the treatment of ulcerative colitis.The risks and the benefits of mesalazine as a treatment for ulcerative colitis.Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis.Review article: medication non-adherence in ulcerative colitis--strategies to improve adherence with mesalazine and other maintenance therapies.Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis.Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease.Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis.Renal effects of long-term treatment with 5-aminosalicylic acidMedical treatment of ulcerative colitisEfficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis.An evidence-based systematic review on medical therapies for inflammatory bowel disease.Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.Alternatives to Sulfasalazine: A Meta-analysis of 5-ASA in the Treatment of Ulcerative Colitis.Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis.
P2860
Q22242348-21673C0D-9639-4714-A2D2-EF60B1E96779Q24185876-A9BBCB31-ED36-4E23-BBA2-E72ACF17F123Q24198024-0A8A897B-CA6A-4198-8978-9746276E0661Q24246220-F4BAF30E-BDFE-432B-865B-FB3D40A1A247Q24248026-A6F2CFA0-2C64-45DA-9F3F-DAFCA470EE99Q26747744-B5FB6382-77B8-40B7-9388-787B93F9E202Q26798299-2630B71A-EDB5-4849-9C55-74B8FB611F18Q26864906-2FC9D4B3-340C-4AEE-BF09-4E48D52AB5E0Q31811146-F68F0FE3-56BB-4A73-954F-6CE14149FB7FQ33950898-051AF1AB-4A0A-4FA9-995A-CEE500817379Q34025054-B5769999-F10C-49F7-A983-01B60BB3B3E4Q34275379-2505E4CF-DBFA-4534-B0DE-E432F8819B81Q34407435-234B52D8-7289-480F-BB35-B336DF3481B5Q34425918-2718DE9E-58AE-4001-AF35-09D66BAB6C51Q34563954-F1C4FB03-758E-4633-A147-2A0678A2C281Q34631685-D5392F20-02AC-44F5-9C6A-95368865873FQ34940520-364FBE2E-6BEA-41A5-8E49-0CEF3B8B3EFFQ35270868-DAC6B128-9AD1-4A38-8F86-8A8474432C29Q35629109-50F83AF7-1939-4AA7-8DEF-E689DB0FF2F6Q35826343-69C03AA7-EC10-427A-B887-1B9AB88AED3EQ35889006-294017F8-C239-4CA0-8BDD-779C2D989D19Q35938450-A6B37E8E-76D4-4756-8B3C-869B3094AA02Q36435889-19285F46-5DA7-42EF-BDA7-9004E440C186Q36645826-1CFFF773-9B91-45ED-8C2F-E5E1EA69CE11Q36762423-D4B99E2D-AD4C-487C-9AFE-A62315889168Q36974888-0B838F98-23E3-49D8-98D2-B5147F209B55Q37123430-A35D3A93-A664-457A-85EA-47CD3EB712F7Q37126870-64F14D7D-C9A6-4A59-909C-653202BD536BQ37135355-86E6EDF2-FF14-475D-89C8-8A3953003917Q37137153-E906916C-72A1-4E83-AA10-B0BCCD492E4FQ37165528-F784A2FE-AF01-463B-BE6E-2DE3BA47C00DQ37183149-46522236-4364-4F51-832F-B25E21A58AE8Q37216699-F68CBED1-DC90-40BA-8E94-9C31D944BB7AQ37223156-5640A207-3D46-42F2-A5E9-6794AC996A79Q37427481-6FB1F91C-BB81-4226-B10F-2C25A85AC931Q37853364-43B633CD-89A6-4CB6-B204-75E8BE3921F6Q37862584-F44C0C24-F7C2-4BB5-8DED-49AEE8BFE4EDQ37892884-560A55DB-BFF3-4EC5-8320-57CE54B26F2BQ38071169-777AAB03-C5D0-46E4-83AF-8B2042F691C9Q38288749-436D3691-F835-4C3D-9D56-8A13AD77CEA0
P2860
Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
Oral mesalamine (Asacol) for m ...... colitis. A multicenter study.
@en
Oral mesalamine
@nl
type
label
Oral mesalamine (Asacol) for m ...... colitis. A multicenter study.
@en
Oral mesalamine
@nl
prefLabel
Oral mesalamine (Asacol) for m ...... colitis. A multicenter study.
@en
Oral mesalamine
@nl
P2093
P1476
Oral mesalamine (Asacol) for m ...... colitis. A multicenter study.
@en
P2093
Sessions JT
Sninsky CA
P304
P356
10.7326/0003-4819-115-5-350
P407
P577
1991-09-01T00:00:00Z